RRAGC

RRAGC Full Name

Ras-related GTP binding C

RRAGC Introduction

Ras-related GTP-binding protein C (RRAGC) is a key regulator of amino acid sensing and one of the core upstream activators of the mechanistic target of rapamycin complex 1 (mTORC1), a signaling pathway that controls cell growth, protein synthesis, metabolism, and autophagy. Researchers investigating cancer, metabolic disorders, or lysosome-dependent signaling frequently focus on RRAGC because abnormalities in nutrient sensing often drive disease progression and therapeutic resistance. RRAGC belongs to the Rag family of small GTPases and functions as a heterodimer with RagA or RagB on the lysosomal membrane, where it determines whether mTORC1 is recruited and activated in response to intracellular amino acid availability. Current evidence consistently identifies RRAGC as an indispensable component of the lysosomal nutrient-sensing machinery, linking environmental nutrient signals with cellular growth, biosynthesis, and metabolic adaptation.

Beyond its established role in nutrient signaling, RRAGC functions as an important integrator of metabolic, epigenetic, and oxidative stress responses. Experimental studies demonstrate that its expression is dynamically regulated by chromatin remodeling and reactive oxygen species, indicating that RRAGC actively participates in cellular adaptation rather than serving solely as a downstream signaling molecule. Additional mechanistic evidence supports the concept that different Rag GTPase heterodimers generate distinct amino acid signaling outputs, with RRAGC providing signaling specificity that fine-tunes mTORC1 activation under changing metabolic conditions. This coordinated regulation enables RRAGC to influence lysosomal biogenesis, autophagy, mitochondrial function, lipid metabolism, and overall cellular homeostasis, making it an important molecular node connecting nutrient availability with long-term metabolic remodeling.

RRAGC has also emerged as a clinically significant disease-associated target across oncology and inherited metabolic disorders. Recurrent activating mutations in RRAGC have been identified in follicular lymphoma, where they maintain mTORC1 signaling even during amino acid deprivation, providing malignant cells with a sustained proliferative advantage. Disease-causing RRAGC variants have likewise been linked to rare developmental disorders characterized by constitutive mTORC1 activation, impaired autophagy, abnormal lysosomal function, and altered cellular metabolism. Functional studies consistently demonstrate that disruption of normal RRAGC regulation uncouples mTORC1 activity from physiological nutrient sensing, leading to persistent anabolic signaling and disease progression. Collectively, current evidence supports RRAGC as both a valuable biomarker of mTOR pathway dysregulation and a promising therapeutic target for precision oncology, metabolic disease research, and the development of next-generation lysosome-targeted therapies.

Alternate Names for RRAGC

RRAGC; Ras-related GTP binding C; ras-related GTP-binding protein C; FLJ13311; GTR2; TIB929; Rag C protein; GTPase-interacting protein 2; RAGC;

• 1.Hwang S, et al.; Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein. BMB Rep. 2020, 53(11):576-581.
  2.Gollwitzer P, et al.; A Rag GTPase dimer code defines the regulation of mTORC1 by amino acids. Nat Cell Biol. 2022, 24(9):1394-1406.